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Integrating GWASs and Human Protein Interaction
Networks Identifies a Gene Subnetwork
Underlying Alcohol Dependence
Shizhong Han,1,2,* Bao-Zhu Yang,1 Henry R. Kranzler,3,4 Xiaoming Liu,5 Hongyu Zhao,6
Lindsay A. Farrer,7 Eric Boerwinkle,5,8 James B. Potash,2 and Joel Gelernter1,9
Despite a significant genetic contribution to alcohol dependence (AD), few AD-risk genes have been identified to date. In the current
study, we aimed to integrate genome-wide association studies (GWASs) and human protein interaction networks to investigate whether
a subnetwork of genes whose protein products interact with one another might collectively contribute to AD. By using two discovery
GWAS data sets of the Study of Addiction: Genetics and Environment (SAGE) and the Collaborative Study on the Genetics of Alcoholism
(COGA), we identified a subnetwork of 39 genes that not only was enriched for genes associated with AD, but also collectively associated
with AD in both European Americans (p < 0.0001) and African Americans (p ¼ 0.0008). We replicated the association of the gene
subnetwork with AD in three independent samples, including two samples of European descent (p ¼ 0.001 and p ¼ 0.006) and one
sample of African descent (p ¼ 0.0069). To evaluate whether the significant associations are likely to be false-positive findings and to
ascertain their specificity, we examined the same gene subnetwork in three other human complex disorders (bipolar disorder, major
depressive disorder, and type 2 diabetes) and found no significant associations. Functional enrichment analysis revealed that the
gene subnetwork was enriched for genes involved in cation transport, synaptic transmission, and transmission of nerve impulses, all
of which are biologically meaningful processes that may underlie the risk for AD. In conclusion, we identified a gene subnetwork
underlying AD that is biologically meaningful and highly reproducible, providing important clues for future research into AD etiology
and treatment.Introduction
Alcohol dependence (AD) (MIM 103780) is a common
psychiatric disorder that is costly to individuals and to
society in the United States and throughout the world.
Although the etiology of AD is complex, family and twin
studies provide strong evidence for a genetic contribution
to its risk, with the estimated heritability ranging from
40% to 60%.1–4 Linkage and candidate gene association
studies have identified several genes that contribute to
AD.5 In recent years, genome-wide association studies
(GWASs) have become a popular approach to identify
common variants associated with human complex
disorders including AD.6–9 However, most published
GWASs of AD relied on analysis at the SNP level; few find-
ings have been genome-wide significant and replicated in
independent samples. More-sophisticated analyses of
existing GWAS data, rather than SNP-level analysis, has
the potential to enhance the identification of true genetic
signals, advance our understanding of its biological
underpinnings, and contribute to the development of
innovative diagnostic and therapeutic strategies.
Gene-set-based analysis of GWASs has been proposed to
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but which might be detectable when examined
jointly.10,11 Gene-set-based analysis is based on the prem-
ise that genes do not work in isolation; instead, genes
that belong to the same molecular networks and cellular
pathways are often involved in disease susceptibility.12,13
Compared with SNP-level analysis, gene-set-based analysis
can potentially detect joint effects or high-order interac-
tions among genes, increase the reproducibility of signifi-
cant findings, and provide more insights into disease
biology. Pathway-based analysis of GWASs is one of several
methods of gene-set-based analysis, which aims to detect
significantly enriched gene sets from predefined canonical
pathways or functional annotations. As a successful
example of a pathway-based approach in GWASs, Wang
et al. identified a significant pathway for Crohn disease
(MIM 266600)—the Il12/Il23 pathway—that was repli-
cated in three independent samples.14 This pathway
included multiple genes that were not detected in any
single GWAS, but were confirmed as risk genes for Crohn
disease through meta-analysis of several GWASs.15 We
applied similar methods, using GWASs and pathway-based
analysis, to study risk genes for cocaine dependence16 and
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Although pathway-based analysis of GWASs has success-
fully identified gene sets associated with complex disor-
ders, these analyses as traditionally performed are
restricted to gene sets defined by prior information that
is often incomplete. In addition, pathway-based analysis
cannot detect genes that work across pathways. Network-
based analysis of GWASs has been proposed as an alternate
approach to pathway-based analysis to search for groups of
functionally related genes within the context of gene
networks. One network-based approach uses information
from a human protein interaction network (HPIN) to
search for a group of genes whose protein products interact
with one another andwhichmay collectively contribute to
disease risk.18 Network-based approaches are more flexible
in defining gene sets, better able to detect genes that work
across pathways, and less biased by prior knowledge than
are pathway-based analysis.
In the current study, we sought to integrate GWASs and
HPINs to identify a gene subnetwork that contributes to
AD risk. Specifically, we aimed to (1) conduct a dense
module search within the HPIN to identify a gene subnet-
work enriched for AD-associated genes by using two GWAS
data sets fromtheStudyofAddiction:Genetics andEnviron-
ment (SAGE) and theCollaborative Studyon theGenetics of
Alcoholism (COGA); (2) assess the association of the gene
subnetwork with AD across five independent case-control
samples; (3) examine the role of the same gene subnetwork
in other human complex disorders; and (4) complete func-
tional enrichment analysis to evaluate whether genes in
the subnetwork share specific functional features.Subjects and Methods
Study Descriptions
We first used two discovery GWAS data sets, SAGE and COGA, to
identify a gene subnetwork enriched for AD-associated genes. To
replicate significant findings, we tested the gene subnetwork in
three independent case-control samples derived from the GWAS
of Alcohol Use and Alcohol Use Disorder in Australian Twin-
Families (OZ-ALC) and from two GWAS data sets of the Yale Uni-
versity School of Medicine and the University of Pennsylvania
Perelman School of Medicine (Yale-Penn). To evaluate its speci-
ficity, we also examined the same gene subnetwork in three other
human complex disorders: bipolar disorder (BD [MIM 125480]),
major depressive disorder (MDD [MIM 608516]), and type 2
diabetes (T2D [MIM 125853]). The basic information for these
GWAS data sets is summarized in Table S1 available online. In
the current study, AD was defined based on DSM-IV criteria. The
control subjects did not meet the DSM-IV criteria of AD, but
some were dependent on other substances, as we described below
for each GWAS data set. All of the work done in this paper was
approved by local institutional review boards and proper informed
consent was obtained. The following sections provide detailed
information for each GWAS data set used in the current study.Discovery Cohort: SAGE and COGA
SAGE aims to identify genetic risk factors and the interplay of
genes and environmental factors for addiction, as described previ-1028 The American Journal of Human Genetics 93, 1027–1034, Deceously.7 The current study included 2,332 unrelated European
Americans (EAs) and 1,088 unrelated African Americans (AAs).
In the SAGE data set, controls were defined as subjects without
dependence on any substance, including cannabis, alcohol,
cocaine, opioids, nicotine, and other substances. The COGA sam-
ples for GWAS were drawn from an ongoing, family-based study of
AD that included subjects from seven sites around the United
States.6,19 After excluding the subjects that overlapped with those
in SAGE, 478 independent subjects were retained for COGA.
Because both COGA and SAGE samples were genotyped on the
same ILLUMINA Human 1 M platform, we merged the 478 inde-
pendent subjects from COGA with SAGE, retaining 2,670 EAs
(1,453 AD and 1,217 controls) and 1,150 AAs (708 AD and 442
controls) for further analysis. In the COGA data set, controls are
subjects who have consumed alcohol but do not meet any defini-
tion of AD or alcohol abuse or any DSM-III-R or DSM-IV definition
of abuse or dependence on other drugs (except nicotine).Replication Cohorts: OZ-ALC and Yale-Penn GWAS
The OZ-ALC sample was drawn from Australian twin-family
samples, which have been used for linkage analysis of smoking-
related traits and alcohol-use disorders.20,21 A family-based
GWAS of alcohol use and AD was constructed from these
families.9 We applied the raw data files from dbGaP that included
6,145 subjects with both phenotype and genotype information,
and most subjects had relatives. To replicate the significant find-
ings in a case-control sample set, we randomly selected 2,228
unrelated subjects (795 AD and 641 controls) from the total
samples for the association analysis. In the OZ-ALC sample, con-
trols were defined as subjects without dependence on alcohol or
nicotine and without depression.
The Yale-Penn GWAS data set included individuals recruited for
genetic studies of cocaine, opioid, and alcohol dependence, as
described previously.16,17,22 Subjects were interviewed with the
Semi-Structured Assessment for Drug Dependence and Alcoholism
(SSADDA) to derive diagnoses for lifetime psychiatric and sub-
stance use disorders based on DSM-IV criteria.23,24 DNA samples
of 5,799 subjects interviewed via the SSADDA were genotyped
on the Illumina HumanOmni1-Quad v1.0 microarray. Because
the genotyped subjects include affected sibling pairs, we randomly
selected 3,008 unrelated AAs (1,641 AD and 1,367 controls) and
1,407 unrelated EAs (1,086 AD and 321 controls) for the associa-
tion analysis. In AAs, controls were defined as subjects without
dependence on any substance, including cannabis, alcohol,
cocaine, opioids, nicotine, and other substances. In EAs, controls
were defined as subjects without dependence on alcohol, though
they could be dependent on other substances, such as cocaine,
opioids, and nicotine.GWAS Data Sets of Other Human Complex Disorders
The GWAS data set of BD included 1,190 cases from the Bipolar
Genome Study (BiGS) and 401 controls, referred to as the
‘‘TGEN’’ sample, which was described previously.25 The Genetics
of Recurrent Early-onset Depression (GenRED) GWAS included
1,020 MDD cases, with 1,636 controls from the Molecular
Genetics of Schizophrenia (MGS) study. Details of the GenRED
GWAS were described elsewhere.26 Two GWAS data sets of T2D
included 9,325 unrelated EAs (626 T2D cases and 8,699 controls)
and 3,096 unrelated AAs (539 T2D cases and 2,557 controls),
which were derived from the Atherosclerosis Risk in Communities
(ARIC) study.27 T2D was defined as fasting glucose R 126 mg/dl,mber 5, 2013
nonfasting glucoseR 200mg/dl, self-reported physician diagnosis
of T2D, or treatment for T2D.Data Quality Control
Each GWAS data set was cleaned before analysis via PLINK.28
Samples and SNPs were excluded from analysis based on predeter-
mined quality control (QC) metrics, including sample call
rate % 95%, SNP call rate % 95%, minor allele frequency
(MAF) % 0.01 in controls, and p values of Hardy-Weinberg
Equilibrium (HWE) tests % 1 3 106 for controls. We used
EIGENSOFT to compute principal components (PC) for samples
in each GWAS data set by using pruned SNPs that were in low
linkage disequilibrium (LD) with one another.29 We removed
outlier subjects from the analysis; these were defined as subjects
whose ancestry was at least three standard deviations from the
mean on one of the two largest PCs.Statistical Analysis
SNP-Level Association Tests
We used PLINK for the SNP-trait association test, with sex, age, and
the top three PCs as covariates under a log-additive genetic model.
We evaluated the possibility of population stratification or other
systemic biases by using the quantile-quantile (QQ) plots based
on p values of autosomal SNPs.
Identification of Modules Enriched for Genes Associated with AD
By using an R package, dmGWAS,30 we conducted a dense module
search within the HPIN to search for modules that were enriched
with small p value genes. We assigned a SNP to a gene if it was
located within the gene or up to 20 kb immediately upstream or
downstream, assigning a gene-level p value to each gene using
the smallest p value among all SNPs mapped to that gene. A
node-weighted HPIN was then constructed by superposing the
gene-level p values on a HPIN from the Protein Interaction
Network Analysis platform (PINA).31 The PINA was obtained
from the PINA website, and the Bioconductor package
‘‘org.Hs.eg.db’’ annotation resource was used to map uniprot IDs
to human official gene symbols, generating ~57,800 protein inter-
action pairs with human gene symbols. The dmGWAS grows the
module from each node by adding the neighboring nodes that
can generate the maximum increment of a module score Zm.
Specifically, Zm ¼
P
Zi=
ﬃﬃﬃ
k
p
, where k is the number of genes in
the module and Zi is transferred from the p value according to
an inverse normal distribution function. Module growth is
stopped if adding neighborhood nodes does not yield an incre-
ment > Zm 3 0.1.
To determine how likely it is that the investigated (index) mod-
ule could be identified by chance, dmGWAS creates a background
distribution by scoring 100,000 randomly selected modules with
the same number of genes as the index module. The significance
of the index module is calculated as the proportion of those
random selected modules whose Zm are larger than or equal to
that of the identified module. To adjust for module size and
make the modules directly comparable to each other, dmGWAS
also calculates a normalized module score Zn, defined as
Zn ¼ ðZm meanðZmðpÞÞÞ=sdðZmðpÞÞ, fromwhich ZmðpÞ represents
the distribution of Zm generated by scoring 100,000 randomly
selected modules with the same size as the index module.
By using the two independent samples (AAs and EAs) from the
merged SAGE-COGA data set, we searched for modules enriched
for AD-associated genes by a dual-evaluation strategy. We first
applied a dense module search in the EA sample and selected theThe American Joutop 5% of ranked modules in the distribution of Zn as candidate
modules for follow up in AAs. We then tested whether the
candidate modules selected in EAs significantly enriched the AD-
associated genes in AAs. The modules that remained significant
after Bonferroni correction in AAs were designated as final candi-
date modules, which were then merged to construct a subnetwork
for further association analysis.
Association Analysis of the Gene Subnetwork
The enrichment of small p value genes in the identified subnet-
work does not necessarily mean that the subnetwork is associated
with AD.We used a permutation-based association test to evaluate
empirically whether the genes in the subnetwork were collectively
associated with AD or the other human complex disorders investi-
gated in the current study.We extracted the subset of data for SNPs
mapped to genes belonging to the subnetwork.We then randomly
reshuffled the phenotypes and genotypes while keeping the
phenotype and genotype correlation structures unchanged. In
each randomly permuted data set, we calculated Zm in exactly
the same way as in the real data set. This process was repeated
10,000 times and 10,000 instances of Zm were obtained to get
the empirical distribution of Zm under the null hypothesis. The
empirical p value for the association of the subnetwork with AD
was estimated by counting the proportion of the Zm that are larger
than or equal to the observed ones in real data across the 10,000
permuted data sets.
Gene Ontology Enrichment Analysis
We submitted the genes in the subnetwork to The Database for
Annotation, Visualization and Integrated Discovery (DAVID) for
gene ontology (GO) term enrichment analysis based on GO level
four annotations.32 Fisher’s exact test was implemented in DAVID
to compute the enrichment p value for each GO term, followed by
Bonferroni correction for multiple testing correction.Results
SNP-Level Association Test in SAGE-COGA Data Set
We conducted association tests for each autosomal SNP
with AD in the merged SAGE-COGA data sets for the EA
and AA samples separately. The QQ plot of p values of
the association tests indicated minimal evidence of popu-
lation stratification or other systematic bias in the merged
SAGE-COGA data sets (Figure S1). Overall, no single SNPs
were identified that met genome-wide significance (p ¼
5.0 3 108), although there were some suggestive associa-
tions. For example, in EAs, the strongest association with
AD was detected for rs10914375 within SERINC2 (MIM
614549) (p¼ 1.93 107, OR¼ 1.38, 95% confidence inter-
val [CI] ¼ 1.22–1.55). In AAs, the strongest association was
found for an intergenic variant rs7182484 (p ¼ 3.53 107,
OR ¼ 1.62, 95% CI ¼ 1.34–1.94). However, the strongest
signal in EAs was not replicated in AAs and vice versa.
The Manhattan plot of the genome-wide association test
results in AAs and EAs are shown in Figure S2.
Identification of Subnetwork Enriched for
AD-Associated Genes
With the merged SAGE-COGA data set, we performed
dense module searching within the HPIN to identify
modules enriched for AD-associated genes. A total ofrnal of Human Genetics 93, 1027–1034, December 5, 2013 1029
Figure 1. Gene Subnetwork Constructed with the Top 5%
Modules Generated in EAs and Replicated in AAs of the Merged
SAGE and COGA GWAS Data Sets
The red-white color gradient of a node is proportional to its
p values. The size of a node is proportional to its degree.8,574 modules were generated in EAs. We selected 429 top-
ranked modules in the 5% upper tail of Zn distribution and
examined them in AAs for enrichment of AD-associated
genes. Of the 429 modules identified in EAs, 7 were also
significant in the enrichment for AD-associated genes after
Bonferroni correction in AAs (pcorrected < 0.05). Table S2
shows the associated genes and statistics for each of the
seven modules. The seven modules, which overlap consid-
erably in their gene content, were then combined to
construct a subnetwork including 39 nonredundant genes.
Figure 1 illustrates the characteristics of the gene subnet-
work. The basic information for each of the 39 genes is
shown in Table S3.Association Tests between the Gene Subnetwork
and AD
We tested the cumulative evidence for association with AD
for all 39 genes in the subnetwork. We observed significant
associations for the gene subnetwork with AD in both EAs
(p < 0.0001) and AAs (p ¼ 0.0008) in the merged SAGE-
COGA GWAS data set, suggesting that the 39-gene subnet-
work was not only enriched for AD-associated genes, but
also collectively associated with AD. We next asked
whether the 39-gene subnetwork would show evidence
of association with AD in independent samples. When
we examined two European ancestry samples and one
African ancestry sample, we found replication of associa-
tion in all three: a European-ancestry Australian sample
from OZ-ALC GWAS (p ¼ 0.006) and the EA (p ¼ 0.001)
and AA (p ¼ 0.0069) samples collected at Yale and Penn.Association Tests between the Gene Subnetwork and
Other Human Complex Disorders
We also examined whether the same gene subnetwork is
associated with other human complex disorders in four1030 The American Journal of Human Genetics 93, 1027–1034, Deceindependent GWAS data sets, including two psychiatric
disorders (BD and MDD) in EAs and one nonpsychiatric
disorder (T2D) in EAs and AAs. We found no significant
evidence for association of this gene subnetwork with BD
(p ¼ 0.53), MDD (p ¼ 0.46), or T2D (EAs, p ¼ 0.41; AAs,
p ¼ 0.25).GO Enrichment Analysis
This analysis revealed a number of GO terms that remained
significantly enriched even after Bonferroni correction
(Table 1). The enriched GO terms related to neuronal
systems are particularly interesting. These include cation
transport, ion transport, synaptic transmission, and trans-
mission of nerve impulses.Discussion
In this study, we identified a subnetwork of 39 genes that
not only was enriched for genes associated with AD, but
also collectively associated with AD in AAs and EAs via
the merged SAGE-COGA GWAS data set. We replicated
the association of the gene subnetwork with AD in each
of three independent samples. We did not find any signif-
icant evidence for association of the same gene subnet-
work with three other human complex disorders (BP,
MDD, or T2D). We thus provided evidence that the finding
is both replicable (even across populations) and, at least to
some extent, specific to AD. Functional enrichment anal-
ysis revealed that the gene subnetwork was enriched for
genes involved in neural processes that could underlie AD.
We sought additional evidence to evaluate whether
genes in the subnetwork were previously implicated in
AD. First, we examined whether these genes were reported
as being associated in previous genetic association studies.
We found that two genes (NCAM1 [MIM 116930], FYN
[MIM 137025]) were reported to be associated with AD in
candidate gene association studies,33–37 although there
was also a negative report for the gene FYN.37 Two other
genes, AKAP9 (MIM 604001) and KCNMA1(MIM
600150), were also reported in an independent GWAS on
alcohol-consuming subjects.38 In addition, GRID2 (MIM
602368) was recently identified as a shared susceptibility
gene for substance use, stress response, obesity, and hemo-
dynamic traits.39 Second, we examined the database
Ethanol-Related Gene Resource (ERGR)40 and found 12
genes in the subnetwork (PRKCE [MIM 176975], KCNMA1,
PTK2 [MIM 600758], DOCK1 [MIM 601403], SDC2 [MIM
142460], GRID2, NRD1 [MIM 602651], NCAM1, STXBP1
[MIM 602926], PRKCA [MIM 176960], RPS6KA2 [MIM
601685], and KCND2 [MIM 605410]) that showed changed
expression levels from alcohol-related microarray gene
expression studies in human, rat, or mouse models. Third,
with the same ERGR database, we examined whether the
subnetwork genes mapped to regions detected in human
linkage studies of AD or alcohol-related behavior quantita-
tive trait loci studies in mouse. This analysis revealed sevenmber 5, 2013
Table 1. GO Enrichment Analysis of Subnetwork Genes
GO Term Overlapping Genesa pb padj
c
GO:0006812~cation transport KCNMA1, KCND2, CLCA1, FYN, KCNE1, KCNIP1, KCNQ1, SCN5A,
KCNMB1, KCNIP4, PRKCB
1.11 3 106 5.06 3 104
GO:0006811~ion transport KCNMA1, KCND2, CLCA1, FYN, KCNE1, GRID2, KCNIP1, KCNQ1,
SCN5A, KCNMB1, KCNIP4, PRKCB
2.82 3 106 0.0013
GO:0007268~synaptic transmission PRKCA, KCNMA1, PTK2, KCND2, GRID2, AKAP9, KCNIP1, KCNMB1 1.10 3 105 0.005
GO:0044057~regulation of system process PRKCA, KCNMA1, AVPR1B, CTNND2, KCNE1, STXBP1, KCNQ1, SCN5A 1.40 3 105 0.0063
GO:0006796~phosphate metabolic process PRKCA, PTK2, RPS6KA2, FYN, TGFA, RAF1, AKAP9, PRKG1, PRKCE,
CDC25A, PRKCB, GUCY2D
2.70 3 105 0.012
GO:0019226~transmission of nerve impulse PRKCA, KCNMA1, PTK2, KCND2, GRID2, AKAP9, KCNIP1, KCNMB1 3.11 3 105 0.014
GO:0006873~cellular ion homeostasis PRKCA, KCNMA1, KCND2, AVPR1B, KCNE1, GRID2, KCNQ1, PRKCB 4.75 3 105 0.021
GO:0008016~regulation of heart contraction PRKCA, AVPR1B, KCNE1, KCNQ1, SCN5A 4.92 3 105 0.022
aSubnetwork genes included in the GO term.
bFisher exact test p value.
cBonferroni correction adjusted p value.genes (PTK2, RGS2 [MIM 600861], NCAM1, STXBP1,
SCN5A [MIM 600163], SORBS1 [MIM 605264], and
CDC25A [MIM 116947]) with linkage evidence for AD or
alcohol-related behavior.
It is notable that 7 genes of the 39 identified encode
potassium channels or their interacting proteins. Potas-
sium channel genes are particularly attractive, because
potassium channels are regulated by alcohol and are key
elements of behavioral tolerance to alcohol in both inverte-
brates and mammals.41 Moreover, in an independent
GWAS, two potassium channel genes, KCNMA1 and
KCNQ5 (MIM 607357), were reported to be associated
withAD,which further supports the potential role of potas-
sium channel genes in AD.38 In our GWAS of opioid depen-
dence, potassium channel genes were also very prominent
among the key findings.17 Because potassium channels
have been major therapeutic targets for drug discovery,42
further research on these channels may contribute to the
development of new drugs for AD treatment.
We performed additional analyses of the gene subnet-
work with AD. First, because the gene subnetwork was
selected on the basis of protein interactions that might
include nonlinear interactions, we tested the gene subnet-
work via the SNP-set (Sequence) Kernel Association Test
(SKAT), which employs a statistical framework that
accounts for both linear and nonlinear interactions.43 We
observed significant associations of the gene subnetwork
with AD in the SAGE-COGA EA (p ¼ 0.00069), OZ-ALC
(p ¼ 0.048), and Yale-Penn AA (p ¼ 0.007) samples, rein-
forcing the genetic associations detected by the smallest
p value method. We did not identify significant associa-
tions in the SAGE-COGA AA (p ¼ 0.12) and Yale-Penn EA
(p ¼ 0.18) samples. We suspect that the nonsignificant
results in the SAGE-COGA AA and Yale-Penn EA samples
were attributable to the lower statistical power of SKAT in
these two samples given their smaller sample sizes and
the greater statistical noise that may exist because SKAT
tested all SNPs within the gene subnetwork. Second, givenThe American Jouthe heterogeneous nature of the DSM-IVAD diagnosis, we
attempted to investigate whether the gene subnetwork was
associated more specifically with some related clinical sub-
phenotypes, such as the presence of alcohol tolerance or
withdrawal symptoms. Our analysis did not reveal any
stronger associations for these two subgroups than for
the AD diagnosis (Table S4). Third, analysis of data strati-
fied by sex did not yield greater statistical associations for
either males or females, suggesting no sex-specific effects
for the gene subnetwork (Table S5).
Our results highlight several advantages of network-
based analysis of GWASs over conventional analytical
strategies to uncover susceptibility genes for AD. First,
network-based analysis may identify genes that could be
missed by traditional univariate analytical approaches.
None of the 39 genes in the subnetwork reached genome-
wide significance (p¼ 53 108) individually and therefore
were unlikely to attract attention in SNP-based GWASs.
Table S6 shows the univariate SNP analysis results with
nominal significance for the 39 gene set in the SAGE-
COGA EA sample. Only six genes (NRD1, CDC25A,
KCNIP1, NCAM1, SGCG [MIM 608896], and GUCY2D
[MIM 600179]) contained SNPs with a significance
level %1 3 104 in the discovery EAs from the SAGE-
COGA data set. We identified these 39 genes in the context
of aHPIN, suggesting that although each could bemodestly
associated with AD, they may collectively be detectable in
AD susceptibility. Second, network-based analysismay pro-
vide more insight into disease biology. Functional enrich-
ment analysis of the genes in the subnetwork revealed a
number of functional annotations that are consistent
with our prior understanding of the neurobiology of AD.
Thus, identification of possible risk genes on the basis of
their inclusion in the subnetwork may provide important
clues to future research into the etiology of AD and poten-
tial targets for its treatment. Third, the significant associa-
tion between the subnetwork and AD was consistently
replicated in three independent data sets, providingrnal of Human Genetics 93, 1027–1034, December 5, 2013 1031
convergent validity for the findings and suggesting poten-
tially higher reproducibility for this kind of system-level
analysis. Fourth, there was no evidence of association
between the subnetwork and other complex human dis-
eases, providing divergent validation for the findings.
Our current study alsohas some limitations. For example,
in the subnetwork construction stage, we arbitrarily
selected modules that were ranked in the top 5% for EAs
and further remained significant after Bonferroni correc-
tion in AAs via the SAGE-COGA data set. Hence, it is likely
that somemodules that contribute to AD susceptibility but
did not meet our module selection criteria could have been
missed. In addition, we used the smallest p valuemethod to
assign the gene-level p values. Under these circumstances,
it is likely that the association signals for genes with mul-
tiple independent risk variants were not well captured.
In conclusion, through the integrated analysis of GWAS
and HPIN, we identified a subnetwork implicated in AD
that is biologically meaningful and highly reproducible.
The genes included in the subnetwork may provide future
targets for research into the etiology and treatment of AD.Supplemental Data
Supplemental Data include Supplemental Acknowledgments, two
figures, and six tables and can be found with this article online at
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